INDIVIOR PHARMACEUTICALS INC

INDVNASDAQ

🏆 #1350 by market capEarnings Oct 29US Equity

$38.07▼ $0.36 (−0.94%)

Live

1h▼ 0.8%

24h▼ 0.9%

7d▼ 1.8%

14d▼ 5.0%

30d▼ 5.3%

1y▲ 66.8%

🏦Market Cap

$4.61B

Small Cap

📈Revenue Growth (YoY)

+13.6%

Healthy

📊Gross Margin

82.0%

High

💵FCF Margin

16.7%

Healthy

⚖️P/S Ratio

3.4x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $37.80 – $38.43
52-Week Range: $21.83 – $42.81
Volume: $2.74B
Avg Volume: $1.84B
Shares Outstanding: 121.0M
Next Earnings: Sep 19, 2026

Fundamentals Snapshot

Annual Revenue: $1.24B
Last Q Revenue: $343M
P/E Ratio: 12.8
P/S Ratio: 3.4x
EPS (TTM): $2.78
Dividend Yield: —

Why Investors Own INDV

✓High-growth profile — revenue up +19.8% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1.24B▲ +20.3% YoY

Gross Margin (TTM)

51.4%▲ +3.2% YoY

Operating Income (TTM)

$370M▲ +20.3% YoY

Free Cash Flow (TTM)

$130M▲ +20.3% YoY

About INDIVIOR PHARMACEUTICALS INC

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

🦦